Lauren Martz, Executive Director of Biopharma Intelligence, leads a discussion on the latest trends in pharmaceutical deals, revealing that bispecifics and degraders are gaining traction while cell and gene therapies are losing favor. Selena Koch, Executive Editor, shares insights from a recent conversation with Denali about advancements in brain shuttles. Karen Koch-Tusman highlights a groundbreaking FDA approval for a vector-based immunotherapy, suggesting potential new standards for treating rare diseases. Chinese biotech's growing influence is also addressed.
